Suzetrigine for Pain After Mohs Surgery

This trial tests two medications to determine which better manages pain after Mohs surgery, a type of skin cancer surgery. Participants will take either suzetrigine, a new potential drug, or the standard pain medication Norco, which combines hydrocodone and acetaminophen. The trial aims to find effective pain relief options for individuals who have undergone this specific dermatologic surgery. Ideal participants are adults who have had a skin tumor removed through Mohs surgery. As a Phase 4 trial, the treatment is already FDA-approved and proven effective, and it seeks to understand how it benefits more patients.

If you are taking medications that interact with the CYP3A pathway, you will need to stop them to participate in this trial.

Research has shown that suzetrigine is generally safe. Studies have found it causes fewer common side effects, such as nausea and dizziness, compared to other pain medications. Most people using suzetrigine do not require additional painkillers. The drug is considered safe and well-tolerated, with only mild or moderate side effects reported. Trials have not observed any serious side effects. The FDA has also approved suzetrigine for treating sudden pain, indicating trust in its safety for this purpose.¹²³⁴⁵

Most treatments for pain after Mohs surgery, like Norco, rely on a combination of hydrocodone and acetaminophen to manage discomfort. But Suzetrigine works differently, as it targets pain through a unique mechanism that researchers believe could reduce dependency on opioids. This novel approach not only aims to manage pain effectively but also addresses concerns related to opioid use, making Suzetrigine an exciting potential alternative in post-surgical pain management.

Research has shown that suzetrigine effectively manages post-surgical pain. In this trial, participants will receive either suzetrigine or the standard care drug, Norco, which combines hydrocodone and acetaminophen. Studies have found that suzetrigine offers pain relief comparable to opioids like hydrocodone but with fewer side effects, such as nausea and vomiting. Most patients rated suzetrigine as providing good to excellent pain relief. It targets pain pathways without the risks associated with opioids. Overall, suzetrigine represents a promising non-opioid option for reducing pain after surgery.⁶⁷⁸⁹¹⁰